Morgan Stanley’s Voyager Therapeutics VYGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.44M | Buy |
697,334
+15,623
| +2% | +$59.2K | ﹤0.01% | 4726 |
|
|
2026
Q1 | $2.63M | Buy |
681,711
+137,597
| +25% | +$542K | ﹤0.01% | 4567 |
|
|
2025
Q4 | $2.14M | Sell |
544,114
-55,574
| -9% | -$246K | ﹤0.01% | 4758 |
|
|
2025
Q3 | $2.8M | Buy |
599,688
+36,249
| +6% | +$131K | ﹤0.01% | 4569 |
|
|
2025
Q2 | $1.75M | Buy |
563,439
+182,954
| +48% | +$590K | ﹤0.01% | 4791 |
|
|
2025
Q1 | $1.29M | Sell |
380,485
-66,656
| -15% | -$311K | ﹤0.01% | 4885 |
|
|
2024
Q4 | $2.54M | Sell |
447,141
-93,522
| -17% | -$603K | ﹤0.01% | 4541 |
|
|
2024
Q3 | $3.16M | Buy |
540,663
+43,694
| +9% | +$318K | ﹤0.01% | 4326 |
|
|
2024
Q2 | $3.93M | Buy |
496,969
+214,809
| +76% | +$1.8M | ﹤0.01% | 4077 |
|
|
2024
Q1 | $2.63M | Buy |
282,160
+38,782
| +16% | +$327K | ﹤0.01% | 4396 |
|
|
2023
Q4 | $2.05M | Sell |
243,378
-50,626
| -17% | -$367K | ﹤0.01% | 4491 |
|
|
2023
Q3 | $2.28M | Sell |
294,004
-489,066
| -62% | -$4.47M | ﹤0.01% | 4307 |
|
|
2023
Q2 | $8.97M | Buy |
783,070
+503,903
| +181% | +$5.21M | ﹤0.01% | 3266 |
|
|
2023
Q1 | $2.15M | Buy |
279,167
+11,914
| +4% | +$94.7K | ﹤0.01% | 4422 |
|
|
2022
Q4 | $1.63M | Sell |
267,253
-80,200
| -23% | -$456K | ﹤0.01% | 4581 |
|
|
2022
Q3 | $2.06M | Buy |
347,453
+220,021
| +173% | +$1.41M | ﹤0.01% | 4410 |
|
|
2022
Q2 | $753K | Sell |
127,432
-23,770
| -16% | -$161K | ﹤0.01% | 5199 |
|
|
2022
Q1 | $1.15M | Sell |
151,202
-268,608
| -64% | -$1.2M | ﹤0.01% | 4893 |
|
|
2021
Q4 | $1.14M | Sell |
419,810
-197,178
| -32% | -$673K | ﹤0.01% | 4978 |
|
|
2021
Q3 | $1.62M | Sell |
616,988
-117,621
| -16% | -$382K | ﹤0.01% | 4735 |
|
|
2021
Q2 | $3.04M | Buy |
734,609
+271,331
| +59% | +$1.23M | ﹤0.01% | 4279 |
|
|
2021
Q1 | $2.18M | Sell |
463,278
-253,055
| -35% | -$1.73M | ﹤0.01% | 4188 |
|
|
2020
Q4 | $5.12M | Buy |
716,333
+684,008
| +2,116% | +$6.58M | ﹤0.01% | 3233 |
|
|
2020
Q3 | $345K | Sell |
32,325
-11,744
| -27% | -$138K | ﹤0.01% | 4828 |
|
|
2020
Q2 | $557K | Buy |
44,069
+10,640
| +32% | +$124K | ﹤0.01% | 4543 |
|
|
2020
Q1 | $306K | Sell |
33,429
-148,274
| -82% | -$1.7M | ﹤0.01% | 4651 |
|
|
2019
Q4 | $2.54M | Sell |
181,703
-49,819
| -22% | -$724K | ﹤0.01% | 3850 |
|
|
2019
Q3 | $3.98M | Buy |
231,522
+214,916
| +1,294% | +$4.51M | ﹤0.01% | 3117 |
|
|
2019
Q2 | $452K | Sell |
16,606
-4,516
| -21% | -$103K | ﹤0.01% | 4653 |
|
|
2019
Q1 | $404K | Sell |
21,122
-95,896
| -82% | -$1.25M | ﹤0.01% | 4688 |
|
|
2018
Q4 | $1.1M | Sell |
117,018
-243,775
| -68% | -$3.13M | ﹤0.01% | 4196 |
|
|
2018
Q3 | $6.83M | Sell |
360,793
-93,926
| -21% | -$1.8M | ﹤0.01% | 2833 |
|
|
2018
Q2 | $8.88M | Sell |
454,719
-11,642
| -2% | -$230K | ﹤0.01% | 2501 |
|
|
2018
Q1 | $8.76M | Buy |
466,361
+294,100
| +171% | +$6.36M | ﹤0.01% | 2466 |
|
|
2017
Q4 | $2.86M | Buy |
172,261
+141,144
| +454% | +$2.42M | ﹤0.01% | 3695 |
|
|
2017
Q3 | $640K | Buy |
31,117
+18,470
| +146% | +$208K | ﹤0.01% | 4722 |
|
|
2017
Q2 | $113K | Sell |
12,647
-10,869
| -46% | -$109K | ﹤0.01% | 5590 |
|
|
2017
Q1 | $311K | Sell |
23,516
-16,119
| -41% | -$196K | ﹤0.01% | 5098 |
|
|
2016
Q4 | $505K | Buy |
39,635
+37,486
| +1,744% | +$481K | ﹤0.01% | 4925 |
|
|
2016
Q3 | $26K | Buy |
2,149
+2,049
| +2,049% | +$27.7K | ﹤0.01% | 5833 |
|
|
2016
Q2 | $1K | Sell |
100
-732
| -88% | -$8.96K | ﹤0.01% | 6447 |
|
|
2016
Q1 | $7K | Buy |
832
+709
| +576% | +$8.04K | ﹤0.01% | 6214 |
|
|
2015
Q4 | $3K | Buy |
+123
| New | +$2.83K | ﹤0.01% | 6466 |
|
Other funds holding VYGR
AC
VPC
OM
Morgan Stanley's VYGR Position: Q2 2026 in Review
Morgan Stanley increased its Voyager Therapeutics (VYGR) stake by 2.3% in Q2 2026, buying an estimated $59.2K and bringing the position to 697,334 shares worth $2.44M. The position accounts for ﹤0.01% of the portfolio, ranked #4726.
Morgan Stanley first reported a position in VYGR in Q4 2015 and has held it in 43 quarters since. The position peaked at $8.97M in Q2 2023. 136 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.
- Morgan Stanley held 697,334 shares of Voyager Therapeutics worth $2.44M as of Q2 2026.
- Morgan Stanley bought 15,623 Voyager Therapeutics shares in Q2 2026, an estimated $59.2K.
- Voyager Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #4726 holding.
- Morgan Stanley first reported a position in Voyager Therapeutics in Q4 2015 and has held it in 43 quarters since.
- Morgan Stanley's Voyager Therapeutics position peaked at $8.97M in Q2 2023.
- 136 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.